About Apogepha
Apogepha is a Healthcare company based in Dresden (Germany). Apogepha is engaged in developing urology-focused pharmaceutical solutions. It operates on a Direct-to-Consumer (D2C) and HealthTech model. Apogepha has completed 1 acquisition, including UroTec. Apogepha offers products and services including APOPROSTAT® forte, FEMALAC®, PROSTUROL®, Uroletics App, and Ryzneuta®. Its focus areas include Pharmaceuticals and Urology.
Company details
Apogepha, through APOGEPHA Arzneimittel GmbH, is dedicated to the development and distribution of pharmaceutical products and services tailored for urological conditions. The company operates primarily in the healthcare sector, focusing on urology with a wide range of products addressing issues such as benign prostate enlargement, urinary tract infections, prostatitis, and bladder cancer. Solutions are provided through innovative medications and digital health applications like Uroletics for prostate cancer patients. Sustainability and patient well-being are emphasized as core values, driving continuous innovation and collaboration within the industry.
- Headquarters Dresden, Germany
- SectorsHealthcare
- Phone•••• ••••
- Website apogepha.de
- Social LinkedIn
- Investments & Acquisitions
Products & Services of Apogepha
Apogepha offers a comprehensive portfolio of products and services, including APOPROSTAT® forte, FEMALAC®, PROSTUROL®, Uroletics App, and Ryzneuta®.
Supports prostate health for benign enlargement issues effectively.
Aids in preventing and treating urinary tract infections.
Provides local relief for prostatitis with hyaluronic acid.
Digital health application for prostate cancer patients.
Introduced for neutropenia treatment in German market.
Investments & Acquisitions by Apogepha
Apogepha has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include UroTec.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gambling services are provided by UroTec in Germany. | urotec.de | Dresden, Germany | 2005 | Sep 2010 | •••• |
Complete acquisition details for Apogepha
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of Apogepha
Websites that share an audience with Apogepha (apogepha.de).
Websites whose visitors overlap most with Apogepha. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| neuraxpharm.com | 91% | 79.2K | #506,953 | View details | |
| betapharm.de | 78% | View details | |||
| bionorica.de | 70% | 90.5K | #405,551 | View details | |
| kranushealth.com | 60% | 22.5K | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Apogepha
Apogepha is headquartered in Dresden, Germany. It is registered at Dresden, Saxony, Germany.
Apogepha, through APOGEPHA Arzneimittel GmbH, is dedicated to the development and distribution of pharmaceutical products and services tailored for urological conditions. The company operates primarily in the healthcare sector, focusing on urology with a wide range of products addressing issues such as benign prostate enlargement, urinary tract infections, prostatitis, and bladder cancer. Solutions are provided through innovative medications and digital health applications like Uroletics for prostate cancer patients. Sustainability and patient well-being are emphasized as core values, driving continuous innovation and collaboration within the industry.
Apogepha offers APOPROSTAT® forte, FEMALAC®, PROSTUROL®, Uroletics App, and Ryzneuta®.
Apogepha has made 1 acquisition, including UroTec.